GlassScriptPhysician profile
Stephanie Sumner
NPI 1013550060
$864.12
in general payments reported to CMS, 2019-2025
17 companies · $264 in 2025
The $264 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3.16 · 2022: $230 · 2023: $225 · 2024: $143 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $631.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $206.38 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.23 | 2022-2023 | Relistor |
| Scilex Pharmaceuticals INC. | $102.69 | 2022-2023 | Ztlido |
| Lilly USA, LLC | $97.25 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Vanda Pharmaceuticals INC. | $64.12 | 2025 | Fanapt |
| Biohaven Pharmaceutical Holding Company LTD. | $59.19 | 2022 | |
| Amgen INC. | $37.94 | 2022 | |
| Novo Nordisk INC | $31.75 | 2024-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $31.20 | 2025 | Airsupra, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.16 | 2025 | Caplyta |
| Collegium Pharmaceutical, INC. | $18.88 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $17.91 | 2024 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.82 | 2024 | Jardiance |
| Relievant Medsystems, INC. | $14.78 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.57 | 2025 | Rexulti |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.09 | 2023 | |
| Genentech USA, INC. | $3.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Sumner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.